Loading…
Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study
Purpose The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), and MD Anderson (MDA) criteria for response asses...
Saved in:
| Published in: | Nuclear medicine and molecular imaging 2018, 52(6), , pp.420-429 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873 |
| container_end_page | 429 |
| container_issue | 6 |
| container_start_page | 420 |
| container_title | Nuclear medicine and molecular imaging |
| container_volume | 52 |
| creator | Gupta, Manoj Choudhury, Partha Sarathi Rawal, Sudhir Goel, Harish Chandra Rao, S. Avinash |
| description | Purpose
The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), and MD Anderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.
Methods
Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CT were included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.
Results
Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (
P
|
| doi_str_mv | 10.1007/s13139-018-0548-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_3891156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2155168970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873</originalsourceid><addsrcrecordid>eNp1kl1v0zAUhiMEYtPYD-AGWeIGpAX8UccOF0gllFFp1ao2XFvGcVpviV3spGg_cP9rTjPKh4RvzpH9nPfYx2-SvETwHYKQvQ-IIJKnEPEU0glPyZPkFPEsT8mE46fHnE1OkvMQbmBcBOeQsOfJCYGUcMbIaXI_28uml51xFrgarGbFfF1egOVsNSaz61VZXABpK7D4PAWFN532RoLaeTANQYdg7AaUXsuu1bYDKx12zgYNfppuCy5lxtPlejGNgmValMBYsNCdDF3sqMDSuyHToJBWaQ-WcXcQOdR-Mk5tdWuUbAZw44dezn4AEhSu3Ukf4b0G666v7l4kz2rZBH3-GM-Sb19mZfE1vbq-nBfTq1RROOlSltWUSEQV5BRWOWYIUwgVpqpGCEOYc1zJOqeomuRSsoqSTCtOcMZqhTFn5Cx5O-paX4tbZYST5hA3Ttx6MV2Vc0F4jhDNIvtxZHf991ZXKj7My0bsvGmlvztU_n1izTbq7EWGs_h3JAq8eRTw7kevQydaE5RuGmm164PAiFKU8ZzBiL7-B71xvbdxFJEiOSKE8kEQjZSKcw9e18fLICgGT4nRUyJ6SgyeEkPNqz9fcaz45aAI4BEI8chutP_d-v-qD1hP1PE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2139133583</pqid></control><display><type>article</type><title>Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study</title><source>Springer Nature</source><source>PubMed Central</source><creator>Gupta, Manoj ; Choudhury, Partha Sarathi ; Rawal, Sudhir ; Goel, Harish Chandra ; Rao, S. Avinash</creator><creatorcontrib>Gupta, Manoj ; Choudhury, Partha Sarathi ; Rawal, Sudhir ; Goel, Harish Chandra ; Rao, S. Avinash</creatorcontrib><description>Purpose
The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), and MD Anderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.
Methods
Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CT were included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.
Results
Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (
P
< 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.
Conclusion
We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.</description><identifier>ISSN: 1869-3474</identifier><identifier>EISSN: 1869-3482</identifier><identifier>DOI: 10.1007/s13139-018-0548-3</identifier><identifier>PMID: 30538773</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antigens ; Biochemistry ; Cardiology ; Comparative studies ; Computed tomography ; Criteria ; Emission analysis ; Gallium ; Imaging ; Medicine ; Medicine & Public Health ; Metastasis ; Morphology ; Nuclear Medicine ; Oncology ; Original ; Original Article ; Orthopedics ; Patients ; Positron emission ; Prostate cancer ; Radiology ; Statistical significance ; Statistical tests ; Tomography ; Tumors ; 방사선과학</subject><ispartof>Nuclear Medicine and Molecular Imaging , 2018, 52(6), , pp.420-429</ispartof><rights>Korean Society of Nuclear Medicine 2018</rights><rights>Korean Society of Nuclear Medicine 2018.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873</citedby><cites>FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873</cites><orcidid>0000-0002-6401-815X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261863/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261863/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30538773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002413802$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Manoj</creatorcontrib><creatorcontrib>Choudhury, Partha Sarathi</creatorcontrib><creatorcontrib>Rawal, Sudhir</creatorcontrib><creatorcontrib>Goel, Harish Chandra</creatorcontrib><creatorcontrib>Rao, S. Avinash</creatorcontrib><title>Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study</title><title>Nuclear medicine and molecular imaging</title><addtitle>Nucl Med Mol Imaging</addtitle><addtitle>Nucl Med Mol Imaging</addtitle><description>Purpose
The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), and MD Anderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.
Methods
Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CT were included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.
Results
Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (
P
< 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.
Conclusion
We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.</description><subject>Antigens</subject><subject>Biochemistry</subject><subject>Cardiology</subject><subject>Comparative studies</subject><subject>Computed tomography</subject><subject>Criteria</subject><subject>Emission analysis</subject><subject>Gallium</subject><subject>Imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Morphology</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Prostate cancer</subject><subject>Radiology</subject><subject>Statistical significance</subject><subject>Statistical tests</subject><subject>Tomography</subject><subject>Tumors</subject><subject>방사선과학</subject><issn>1869-3474</issn><issn>1869-3482</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kl1v0zAUhiMEYtPYD-AGWeIGpAX8UccOF0gllFFp1ao2XFvGcVpviV3spGg_cP9rTjPKh4RvzpH9nPfYx2-SvETwHYKQvQ-IIJKnEPEU0glPyZPkFPEsT8mE46fHnE1OkvMQbmBcBOeQsOfJCYGUcMbIaXI_28uml51xFrgarGbFfF1egOVsNSaz61VZXABpK7D4PAWFN532RoLaeTANQYdg7AaUXsuu1bYDKx12zgYNfppuCy5lxtPlejGNgmValMBYsNCdDF3sqMDSuyHToJBWaQ-WcXcQOdR-Mk5tdWuUbAZw44dezn4AEhSu3Ukf4b0G666v7l4kz2rZBH3-GM-Sb19mZfE1vbq-nBfTq1RROOlSltWUSEQV5BRWOWYIUwgVpqpGCEOYc1zJOqeomuRSsoqSTCtOcMZqhTFn5Cx5O-paX4tbZYST5hA3Ttx6MV2Vc0F4jhDNIvtxZHf991ZXKj7My0bsvGmlvztU_n1izTbq7EWGs_h3JAq8eRTw7kevQydaE5RuGmm164PAiFKU8ZzBiL7-B71xvbdxFJEiOSKE8kEQjZSKcw9e18fLICgGT4nRUyJ6SgyeEkPNqz9fcaz45aAI4BEI8chutP_d-v-qD1hP1PE</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Gupta, Manoj</creator><creator>Choudhury, Partha Sarathi</creator><creator>Rawal, Sudhir</creator><creator>Goel, Harish Chandra</creator><creator>Rao, S. Avinash</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>대한핵의학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-6401-815X</orcidid></search><sort><creationdate>20181201</creationdate><title>Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study</title><author>Gupta, Manoj ; Choudhury, Partha Sarathi ; Rawal, Sudhir ; Goel, Harish Chandra ; Rao, S. Avinash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Biochemistry</topic><topic>Cardiology</topic><topic>Comparative studies</topic><topic>Computed tomography</topic><topic>Criteria</topic><topic>Emission analysis</topic><topic>Gallium</topic><topic>Imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Morphology</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Prostate cancer</topic><topic>Radiology</topic><topic>Statistical significance</topic><topic>Statistical tests</topic><topic>Tomography</topic><topic>Tumors</topic><topic>방사선과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Manoj</creatorcontrib><creatorcontrib>Choudhury, Partha Sarathi</creatorcontrib><creatorcontrib>Rawal, Sudhir</creatorcontrib><creatorcontrib>Goel, Harish Chandra</creatorcontrib><creatorcontrib>Rao, S. Avinash</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Manoj</au><au>Choudhury, Partha Sarathi</au><au>Rawal, Sudhir</au><au>Goel, Harish Chandra</au><au>Rao, S. Avinash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study</atitle><jtitle>Nuclear medicine and molecular imaging</jtitle><stitle>Nucl Med Mol Imaging</stitle><addtitle>Nucl Med Mol Imaging</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>52</volume><issue>6</issue><spage>420</spage><epage>429</epage><pages>420-429</pages><issn>1869-3474</issn><eissn>1869-3482</eissn><abstract>Purpose
The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), and MD Anderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.
Methods
Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CT were included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.
Results
Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (
P
< 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.
Conclusion
We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30538773</pmid><doi>10.1007/s13139-018-0548-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6401-815X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1869-3474 |
| ispartof | Nuclear Medicine and Molecular Imaging , 2018, 52(6), , pp.420-429 |
| issn | 1869-3474 1869-3482 |
| language | eng |
| recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_3891156 |
| source | Springer Nature; PubMed Central |
| subjects | Antigens Biochemistry Cardiology Comparative studies Computed tomography Criteria Emission analysis Gallium Imaging Medicine Medicine & Public Health Metastasis Morphology Nuclear Medicine Oncology Original Original Article Orthopedics Patients Positron emission Prostate cancer Radiology Statistical significance Statistical tests Tomography Tumors 방사선과학 |
| title | Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A27%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20RECIST,%20PERCIST,%20EORTC,%20and%20MDA%20Criteria%20for%20Assessing%20Treatment%20Response%20with%20Ga68-PSMA%20PET-CT%20in%20Metastatic%20Prostate%20Cancer%20Patient%20with%20Biochemical%20Progression:%20a%20Comparative%20Study&rft.jtitle=Nuclear%20medicine%20and%20molecular%20imaging&rft.au=Gupta,%20Manoj&rft.date=2018-12-01&rft.volume=52&rft.issue=6&rft.spage=420&rft.epage=429&rft.pages=420-429&rft.issn=1869-3474&rft.eissn=1869-3482&rft_id=info:doi/10.1007/s13139-018-0548-3&rft_dat=%3Cproquest_nrf_k%3E2155168970%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c504t-76f53a15c0850d92712500c25cf11200982daf951d49aa7d536ec83267fc22873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2139133583&rft_id=info:pmid/30538773&rfr_iscdi=true |